文献速递肺栓塞与肺血管病间质性肺疾病

口服高香草酸治疗肺动脉高压的随机安慰剂对照试验

Randomised, placebo-controlled trial of oral hymecromone in adults with pulmonary hypertension.
PubMed 文献 · Thorax · 2025-08-15

这项IIa期随机双盲安慰剂对照研究纳入16例肺动脉高压(PH)成人患者,按5:3随机分组接受口服高香草酸或安慰剂治疗24周。主要终点肺血管阻力(PVR)组间无显著差异(平均差0.61 Wood单位,95%CI -1.5至2.7)。探索性分析提示PH-ILD亚组6分钟步行距离较基线平均增加66米(SD 69.6),生活质量改善。

要点

  • 口服高香草酸24周未显著改善肺血管阻力。
  • 无导致停药的治疗相关不良事件。
  • PH-ILD亚组6分钟步行距离和生活质量有改善信号。

核心结论

  • 口服高香草酸24周未显著改变肺动脉高压患者的肺血管阻力。
  • 探索性分析提示PH-ILD患者功能参数和生活质量可能改善,需更大样本验证。

研究设计与样本

  • IIa期概念验证随机双盲安慰剂对照研究,纳入16例肺动脉高压(含PH-ILD)成人患者。
  • 按5:3随机分组并 stratified by PH group,口服高香草酸或安慰剂每日两次共24周。

主要发现

  • 24周时实验组与安慰剂组肺血管阻力无统计学显著差异(平均差0.61 Wood单位,95%CI -1.5至2.7)。
  • 5例接受高香草酸治疗的PH-ILD患者6分钟步行距离从基线至24周未经调整的绝对平均增加66米(SD 69.6),生活质量指标改善。
  • 无导致高香草酸停药的治疗相关不良事件。

关键数值与推荐

  • 主要终点为肺血管阻力变化,组间平均差0.61 Wood单位(95%CI -1.5至2.7)。
  • PH-ILD亚组6分钟步行距离平均增加66米(SD 69.6)。

临床怎么用

  • 目前证据不支持口服高香草酸作为肺动脉高压的常规逆转重构治疗。
  • PH-ILD患者的功能改善信号需在更大样本中进一步验证。

局限性

  • 样本量小(16例),探索性分析结果需谨慎解读。
  • PH-ILD亚组仅5例,功能改善为非调整分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary hypertension (PH) is a progressive cardiopulmonary condition associated with increased morbidity and mortality. The extracellular matrix component hyaluronan (HA) is linked to vascular remodelling and interstitial fibrosis in PH. We hypothesised that inhibition of HA synthesis with hymecromone could serve as a reverse-remodelling therapy in PH. METHODS: We performed a proof-of-concept phase IIa randomised, double-blind, placebo-controlled study in adults with pulmonary arterial hypertension and PH associated with interstitial lung disease (PH-ILD). Patients were randomised to a 5:3 ratio and stratified by PH group to receive oral hymecromone or placebo two times per day over 24 weeks. The primary endpoint was change in pulmonary vascular resistance (PVR). RESULTS: We enrolled 16 patients with PH with a median age of 62.0 years. There were no treatment-related adverse events leading to hymecromone discontinuation. No statistically significant difference in PVR was observed at 24 weeks for the experimental group compared with the placebo group (mean difference 0.61 Wood unit, 95% CI -1.5 to 2.7). Five patients with PH-ILD treated with hymecromone demonstrated an unadjusted absolute mean increase in 6 min walk distance of 66 m (SD 69.6) from baseline to 24 weeks and improvements in quality-of-life measures. CONCLUSION: Our exploratory analyses suggest that treatment with hymecromone could lead to improvements in clinically meaningful functional parameters in patients with PH-ILD. Further investigations in larger patient cohorts are warranted. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT05128929.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Czepiel K, Nagy N, Panjalingam T, et al. Randomised, placebo-controlled trial of oral hymecromone in adults with pulmonary hypertension. Thorax. 2025. PMID: 40451287. doi:10.1136/thorax-2024-222725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。